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[18F]Atorvastatin: synthesis of a potential
molecular imaging tool for the assessment
of statin-related mechanisms of action
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Abstract
Background: Statins are lipid-lowering agents that inhibit cholesterol synthesis and are clinically used in the
primary and secondary prevention of cardiovascular diseases. However, a considerable group of patients does not
respond to statin treatment, and the reason for this is still not completely understood. [18F]Atorvastatin, the 18F-
labeled version of one of the most widely prescribed statins, may be a useful tool for statin-related research.
Results: [18F]Atorvastatin was synthesized via an optimized ruthenium-mediated late-stage 18F-deoxyfluorination.
The defluoro-hydroxy precursor was produced via Paal-Knorr pyrrole synthesis and was followed by coordination of
the phenol to a ruthenium complex, affording the labeling precursor in approximately 10% overall yield.
Optimization and automation of the labeling procedure reliably yielded an injectable solution of [18F]atorvastatin in
19% ± 6% (d.c.) with a molar activity of 65 ± 32 GBq·μmol−1. Incubation of [18F]atorvastatin in human serum did not
lead to decomposition. Furthermore, we have shown the ability of [18F]atorvastatin to cross the hepatic cell
membrane to the cytosolic and microsomal fractions where HMG-CoA reductase is known to be highly expressed.
Blocking assays using rat liver sections confirmed the specific binding to HMG-CoA reductase. Autoradiography on
rat aorta stimulated to develop atherosclerotic plaques revealed that [18F]atorvastatin significantly accumulates in
this tissue when compared to the healthy model.
Conclusions: The improved ruthenium-mediated 18F-deoxyfluorination procedure overcomes previous hurdles
such as the addition of salt additives, the drying steps, or the use of different solvent mixtures at different phases of
the process, which increases its practical use, and may allow faster translation to clinical settings. Based on tissue
uptake evaluations, [18F]atorvastatin showed the potential to be used as a tool for the understanding of the
mechanism of action of statins. Further knowledge of the in vivo biodistribution of [18F]atorvastatin may help to
better understand the origin of off-target effects and potentially allow to distinguish between statin-resistant and
non-resistant patients.
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Background
Cardiovascular diseases represent one of the leading
causes of death globally [1]. Atherosclerosis, a chronic
inflammatory pathology characterized by deposition of
plaques (a collection of fat, cholesterol, calcium, fibrin,
and cellular waste products) in the walls of arteries, is
the dominant cause of cardiovascular diseases [2]. The
partial rupture and detachment of these plaques increase
the risk of clogging the blood flow, which, ultimately,
can lead to highly incapacitating or even mortal condi-
tions such as myocardial infarction or cerebrovascular
accidents [3]. The exact cause of atherosclerosis remains
a subject of discussion and has been connected to sev-
eral distinct mechanisms, hypotheses, and theories [4–
16]. Nonetheless, despite its complexity, atherosclerosis
is generally correlated to the levels of cholesterol in
plasma [17–22]. HMG-CoA (3-hydroxy-3-methyl-gluta-
ryl-coenzyme A) reductase is involved in the biosyn-
thesis of cholesterol and is subject to feedback
regulation by end-products of this same pathway [23–
26]. Thus, inhibition of HMG-CoA reductase with sta-
tins became an essential strategy for the primary preven-
tion of atherosclerosis. Statins contain a
dihydroxycarboxylic acid moiety that mimics and out-
competes the natural substrate molecule HMG-CoA,
preventing its reduction to mevalonate and further chol-
esterol synthesis [27, 28] (Fig. 1a).
In addition to the cholesterol-lowering action, the suc-
cess of statins became increasingly connected with
broader pleiotropic effects [29–32]. Statins are increas-
ingly being associated with potential protective effects
on pathologies beyond cardiovascular diseases (e.g., re-
spiratory [33–37], carcinogenic [38–43], viral [44–48],
neurodegenerative [49–53]). The exact off-target mecha-
nisms of statins, along with the reason why many pa-
tients show resistance to this class of drugs, are still
unknown. Therefore, an increase of specific knowledge
of the subcellular mechanisms affected by statins and
the development of a more sensitive tool to investigate
this subject are currently challenging hot topics in medi-
cinal chemistry [54, 55]. High-resolution molecular im-
aging modalities, such as positron emission tomography
(PET), together with sensitive nuclear analytical tech-
niques relying on radiolabeled molecules, can help in a
better understanding by mapping the biodistribution
profile over time within complex living organisms. To
this purpose, we report the 18F-labeling of atorvastatin
(12), one of the most widely used statins in the preven-
tion of cardiovascular risk factors and one of the best-
selling drugs in pharmaceutical history [56]. Exchanging
the aryl fluoride with its 18F radioisotope enables the
radiolabeling of atorvastatin without changing its
pharmacological properties. However, in the case of
atorvastatin, the 18F-fluorination of electron-rich arenes
is a classical struggle in radiochemistry and has chal-
lenges associated with synthesis automation [57]. The
fluorine-containing aromatic ring within the atorvastatin
structure is electron-rich, and therefore, we use the
ruthenium-mediated radiodeoxyfluorination strategy
[58–60] to synthesize [18F]atorvastatin ([18F]12). This
radiotracer may have the potential to become an attract-
ive tool for statin-related research, enabling the under-
standing of cellular and subcellular mechanisms, the
identification of off-target activity and, ultimately, allow-
ing to select between statin-resistant and non-resistant
patients for targeted therapy.
Fig. 1 Role of HMG-CoA reductase in the synthesis of cholesterol (a) and structure of some of the most clinically used statins (b)
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Results
Synthesis of precursors and 18F-fluorination strategy
The synthesis of the benzyl ether pyrrole intermediate 6,
as well as the atorvastatin precursor 11, was performed
by the treatment of the corresponding 1,4-diketone in-
termediates 4 and 10, respectively, with the commer-
cially available primary amine 5 in a pivalic acid-
catalyzed Paal-Knorr condensation reaction (Scheme 1).
The 1,4-diketone intermediates 4 and 10 were synthe-
sized via a Stetter reaction [61, 62]. In summary, the α,β-
unsaturated ketone 1 was combined with benzaldehydes
2 and 9, respectively, in the presence of triethylamine
and the thiazolium bromide catalyst 3 to afford the cor-
responding 1,4-diketone intermediates 4 and 10, re-
spectively. Atorvastatin (12) was obtained from its
precursor 11 after near quantitative removal of the
ketal-ester protecting groups in the side-chain with se-
quential hydrochloric acid and sodium hydroxide
treatment.
For the radiofluorination of atorvastatin, the benzyl
ether pyrrole intermediate 6 was synthesized and subse-
quently converted to the corresponding phenol 7 by
palladium on carbon (Pd/C)-catalyzed hydrogenolysis
(Scheme 2). Coordination of 7 to ruthenium (II) de-
creases its π-electron density, providing 8, and activates
the precursor towards radiodeoxyfluorination [58–60].
Radiochemistry optimization: improvement and
simplification of the Ru-mediated 18F-deoxyfluorination
Synthesis of [18F]atorvastatin ([18F]12) started with con-
ventional trapping of the aqueous [18F]fluoride, pro-
duced by a cyclotron using the 18O(p,n)18F nuclear
reaction, on an anion exchange cartridge (Chromafix 45-
PS-HCO3
−). The [18F]fluoride was then eluted from the
cartridge with a solution of the labeling precursor 8
(2.5 μmol), N,N-bis(2,6-diisopropylphenyl-1-chloroimi-
dazolium chloride (13, 6.0 equiv.), and bis(trimethylneo-
pentylammonium) oxalate in a mixture of ethanol:
pivalonitrile:veratrole (400 μL, 1:4:4 v:v:v) directly into a
reaction vial [60]. The reaction mixture was heated
under vigorous stirring at 140 °C for 30 min to afford the
key intermediate [18F]11. A drawback of this literature
procedure is the reduced elution efficiency from the
anion exchange cartridge. Besides, there is no
Scheme 1 Synthesis of ketal and tert-butyl ester side-chain protected benzyl ether pyrrole intermediate 6 and atorvastatin precursor 11
Scheme 2 [18F]Atorvastatin ([18F]12) synthesis approach used in this work
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commercial supplier of the oxalate salt. This may hinder
good manufacturing/radiopharmaceutical/clinical prac-
tice (GMP/GRPP/GCP) applications with the synthe-
sized radiotracer as additional analytical evaluations,
toxicity tests, and reliable and established production of
the additive may be needed to comply with potential
clinical trials in human patients [63]. As mentioned in a
previous report [58], salt additives tend to reduce the
18F-deoxyfluorination yield even though the elution effi-
ciency is increased. Thus, in this work, several readily
available additives were evaluated in order to achieve a
better elution alternative that can increase the elution ef-
ficiency while minimally affecting the 18F-deoxyfluorina-
tion yield (Table 1).
As expected, most of the tested additives have a nega-
tive effect on the 18F-deoxyfluorination yield. The use of
bis(trimethylneopentylammonium) oxalate [58–60] gave
the best overall yields of [18F]11. This addition still de-
creases the 18F-deoxyfluorination conversion by approxi-
mately 10% when compared to the experiments without
an eluent additive. An acceptable alternative to the oxal-
ate seems to be the use of the commercially available
tetrabutylammonium chloride, which, despite lowering
the elution efficiency, led to a similar [18F]11 yield.
Further experiments showed that in the absence of an
eluent additive, the elution efficiency can be more than
doubled by reversely loading and eluting the 45-PS-
HCO3
− cartridge or by replacing this cartridge to a short
1/16″ PTFE tubing filled with approximately 10 mg of a
Biorad MP-1 resin (Fig. 2). However, reversing the cart-
ridge cannot easily be implemented in most automated
modules. Also, since the MP-1 mini-cartridge is not
commercially available and should, therefore, be manu-
ally prepared, it might result in significant elution differ-
ences from batch to batch, which will affect the activity
yield. This led us to the evaluation of different solvent
systems (without the use of eluent additives) to increase
the elution efficiency (Table 2).
By changing the solvents used to dissolve the labeling
precursor 8 and the chloroimidazolium chloride 13,
while keeping all other reaction conditions unchanged,
we were able to improve not only the elution efficiency
but also the yield of the 18F-deoxyfluorination to achieve
the intermediate product [18F]11. Using a mixture of
methanol:veratrole (1:3 v:v) or methanol:DMSO (1:3 v:v)
provided the best results. However, the mixture with
veratrole quickly builds up high pressure in the reaction
vial at 140 °C (with some associated radioactivity escape).
Thus, replacing veratrole by dimethylsulfoxide (DMSO)
is the safer choice of solvent. This optimized method
boosted and simplified the 18F-deoxyfluorination tech-
nique by avoiding the addition of salt additives, skipping
any need for washing the trapped [18F]fluoride, circum-
venting time-consuming azeotropic drying (with the
consequent radioactivity losses by natural decay, evapor-
ation, and unspecific adsorption to the reactor surface)
and the use of different solvent mixtures for the various
steps of the process (elution and 18F-fluorination). The
amount of Ru-coordinated precursor 8 was also reduced
in relation to the previously reported 18F-deoxyfluorina-
tion works (2.5 μmol vs. 5.0 μmol) [58–60]. During the
optimization work, it became evident that some proced-
ure deviations such as air bubbling instead of stirring,
absence of mechanical mixing, increased solvent vol-
umes, larger reaction vials, or flat-shaped bottom ones
can decrease the final 18F-deoxyfluorination yield. In
order to enhance the radiolabeling efficiency, these are
features that should be considered when choosing the
most suitable radiosynthesis module.
Additionally, an exciting finding is the relative toler-
ance of 18F-deoxyfluorination to the presence of water,
which allowed direct fluorination using aqueous
[18F]fluoride from the cyclotron target without the need
Table 1 Influence of eluent additives in the synthesis of the intermediate product [18F]11
Eluent additive Elution efficiencya TLC conversion HPLC purity [18F]11 yieldb
Bis(trimethylneopentylammonium) oxalate 75% 83% 80% 50%
Kryptofix 222, K2C2O4 86% 59% 48% 24%
Tetraethylammonium bicarbonate 54% 34% 50% 9%
Tetrabutylammonium chloride 62% 91% 82% 46%
Sodium acetate 12% 10% 15% 0.2%
Silver acetate 67% 29% 82% 16%
Silver triflate 65% 69% 36% 16%
Sodium oxalate 54% 52% 71% 20%
None 42% 85% 90% 32%
aCalculated by the ratio between the [18F]fluoride trapped in the anion exchange cartridge (45-PS-HCO3
−) and the radioactivity recovered (without reversing the
cartridge) in the reaction vial
bNon-isolated 18F-deoxyfluorination yield based on radio-TLC and radio-HPLC analysis of the crude product and having in consideration the elution efficiency
resulting from the salt additive used in relation to the starting radioactivity. The final percentage of [18F]11 yield was determined by multiplying the elution
efficiency with radio-TLC conversion of the starting [18F]fluoride and with radio-HPLC purity (n ≥ 2)
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Fig. 2 Anion exchange cartridge alternatives tested in this work. a Sep-Pak Accell Plus QMA Plus Light Cartridge (Waters). b 45-PS-HCO3
−
(Chromafix). c Reversed 45-PS-HCO3
− (Chromafix). d Handmade 1/16″ PTFE tubing with MP-1 resin (Biorad)
Table 2 Influence of the solvent system in the synthesis (without eluent additives) of the intermediate product [18F]11
Solvent (400 μL) Elution efficiencyc TLC conversion HPLC purity [18F]11 yieldd
Ethanol:pivalonitrile:veratrole (1:4:4) 42% 85% 90% 32%
Ethanol:acetonitrile:DMSO (1:4:4) 69% 75% 80% 41%
Veratrole 30% 85% 61% 16%
Pivalonitrile 35% 80% 63% 18%
Dimethyl sulfoxide (DMSO) 57% 68% 64% 25%
Methanol:DMSO (1:2) 86% 64% 72% 40%
Methanol:DMSO (1:3) 86% 95% 92% 75%
Methanol:DMSO (1:3.5) 85% 86% 87% 64%
Methanol:DMSO (1:7) 65% 55% 90% 32%
Butanol:DMSO (1:2) 50% 20% 23% 2%
Butanol:DMSO (1:3) 54% 80% 79% 34%
Ethanol:DMSO (1:3.5) 70% 78% 78% 43%
Water:DMSO (1:17) 36% 85% 83% 25%
Aqueous [18F]fluoride:DMSO (3:97)a 100% (no cartridge) 92% 91% 84%
Methanol:veratrole (1:3) 90% 94% 97% 82%
Methanol + veratrole:pivalonitrile (1:1)b 93% (56%) 85% 94% 74% (45%)
a30 μL of aqueous [18F]fluoride was directly added (no elution cartridge needed) to the DMSO solution containing 8 and 13 and left to react
b300 μL of methanol was used to dissolve 8 and 13 to elute the cartridge. Methanol was then evaporated, and the solvent exchanged to 400 μL of
veratrole:pivalonitrile (1:1 v:v) for the reaction. This method, despite having high elution efficiency (93%), showed significant losses (up to 45%) of the eluted
[18F]fluoride during the evaporation of methanol. Thus, the real efficiency and [18F]11 yield is shown in brackets
cCalculated by the ratio between the [18F]fluoride trapped in the anion exchange cartridge (45-PS-HCO3
−) and the radioactivity recovered (without reversing the
cartridge) in the reaction vial
dNon-isolated 18F-deoxyfluorination yield based on radio-TLC and radio-HPLC analysis of the crude product and having in consideration the elution efficiency
resulting from the solvent mixture used in relation to the starting radioactivity. The final percentage of [18F]11 yield was determined by multiplying the elution
efficiency with radio-TLC conversion of the starting [18F]fluoride and with radio-HPLC purity (n ≥ 2)
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for anion exchange cartridges. The drawback is the low
volume of aqueous [18F]fluoride that can be used, which
limits the amount of radioactivity in the reaction. Never-
theless, this is potentially a suitable method for small-
scale productions aimed, for example, for in vitro
evaluations.
Automated synthesis of [18F]atorvastatin ([18F]12)
The optimized procedures were translated to the Syn-
thra RNplus radiosynthesizer. Minimal modifications
were made to the commercial configuration of the mod-
ule (Fig. 3). All unused loading ports to the reaction vial
were closed with perfluoroalkoxy plugs, except one that
was left open with an ethylene tetrafluoroethylene fe-
male luer-to-male fitting for connection to an exhaust
alumina N cartridge (Waters). In summary, aqueous
[18F]fluoride was trapped on a Chromafix 45-PS-HCO3−
anion exchange cartridge preactivated by sequentially
passing 3 mL of K2C2O4 (10 mg/mL) and 2mL of water
and dried with a flow of argon (trapping efficiency, 94%
± 4%; n = 10). After drying the resin in the cartridge
under helium flow for approximately 1 min, the trapped
[18F]fluoride was eluted by pushing a solution of the Ru-
coordinated labeling precursor 8 (2.5 μmol) and N,N-
bis(2,6-diisopropylphenyl-1-chloroimidazolium chloride
(13, 6.0 equiv.) in methanol:DMSO (1:3 v:v, 0.4 mL) over
2 min through the cartridge, directly to a reaction vial
preheated at 110 °C (elution efficiency, 88 ± 5%; n = 10).
This preheating seems to avoid the significant radio-
activity losses that were seen when rapidly increasing
from room temperature to the reaction temperature or
when the reaction vial was already set at 140 °C. The re-
action was left to stir for 30 min at 140 °C to produce
the intermediate [18F]11 (18F-deoxyfluorination yield es-
timated by multiplying radio-TLC conversion of
[18F]fluoride with radio-HPLC purity, 87 ± 9%; n = 10).
The ketal and tert-butyl protecting groups were removed
by sequentially treating the reaction mixture with 1 mL
of methanol:HCl 6M (49:1 v:v) at 60 °C for 5 min,
followed by addition of 0.5 mL of methanol:aqueous
NaOH 50% (9:1 v:v) and stirring at 60 °C for another 5
min. HPLC analysis revealed the complete absence of
the intermediate [18F]11 from the reaction mixture. The
content of the reaction vial was automatically loaded
onto the built-in preparative HPLC (with UV and radio-
activity detector) to collect the [18F]atorvastatin
([18F]12) fraction. Final solid-phase extraction (SPE) en-
abled the solvent exchange, and [18F]12 was then refor-
mulated in a physiological and injectable calcium acetate
solution to mimic the atorvastatin (12) calcium prepar-
ation in which the therapeutic dose of this drug is gener-
ally administered. The radiochemical yield of
[18F]atorvastatin ([18F]12) was 19 ± 6%, n = 10 (d.c.),
and the molar activity was 65 ± 32 GBq·μmol−1 (n = 10)
at the end of synthesis. The activity yield achieved for
[18F]12 was 1.3 ± 0.4 GBq (n.d.c.) when starting with 9.6
± 1.9 GBq of aqueous [18F]fluoride produced in cyclo-
tron (n = 10).
Stability tests and characterization of [18F]atorvastatin
([18F]12)
The final purified and formulated radiotracer was com-
pared with the corresponding non-radioactive reference
standard by analytical radio-HPLC to confirm identity
(Fig. 4). [18F]Atorvastatin ([18F]12) showed a radiochem-
ical purity always higher than 95%, and no sign of
Fig. 3 Overall scheme of the full Synthra RNplus setup used
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Fig. 4 Analytical HPLC profiles (red: γ detector, blue: UV detector) of [18F]atorvastatin ([18F]12), standard atorvastatin (12), radiofluorinated
intermediate [18F]11, non-radioactive intermediate 11, and Ru-coordinated labeling precursor 8
Fig. 5 In vitro autoradiography with [18F]atorvastatin ([18F]12) on rat liver tissue counterparts without (control) and with (blocked) standard
atorvastatin (12) pre-treatment
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decomposition was observed for at least 4 h in solution
at room temperature. Incubation of the radiotracer ei-
ther in human (collected off the clot from healthy volun-
teers) or in Wistar rat serum at 37 °C for up to 4 h
indicated an in vitro stability of > 95%. Log D was mea-
sured to confirm the lipophilicity of the radiotracer with
the one described for atorvastatin (12). An experimental
log D of 1.61 ± 0.12 (pH 7.4, n = 4) was measured, being
in accordance with the reported values (log D approx.
1.5 [64]).
Evaluation of [18F]atorvastatin ([18F]12) in rat liver
homogenates and tissue autoradiography
HMG-CoA reductase is highly expressed in the liver,
where it is subject to hormonal, dietary, and pharmaco-
logical regulation [65–67]. Evaluation of [18F]atorvastatin
([18F]12) in rat liver homogenates revealed that 87% ±
4% (n = 4) of the radioactivity is found in the micro-
somal and cytosolic fractions, which is in accordance
with known enzyme distribution [68]. Further radio-
TLC assessment showed the absence of degradation and
18F-defluorination. Blocking assays using rat liver sec-
tions with and without standard atorvastatin (12) pre-
treatment were performed to evaluate [18F]atorvastatin
([18F]12) binding selectivity to the HMG-CoA reductase
(Fig. 5). The comparison of [18F]atorvastatin ([18F]12)
uptake between non-treated and treated liver sections
showed an average 60% ± 8% decrease in the binding of
the radiotracer after blocking (p < 0.0001).
The potential of [18F]atorvastatin ([18F]12) to be used
as a PET tracer for atherosclerosis imaging was also pre-
liminarily evaluated by autoradiography of the aorta
from a normal and an atherosclerotic rat model. Due to
a reduction of lipoprotein clearance, apolipoprotein E-
deficient rats fed with high-cholesterol diet tend to de-
velop elevated plasma levels of cholesterol and to form
atherosclerotic plaques [69, 70]. Incubation of the aorta
excised from a validated rat model for atherosclerosis
[71] with the radiotracer showed high [18F]atorvastatin
([18F]12) uptake in the atherosclerotic aorta (Fig. 6). The
radiotracer uptake is reduced when this aorta is pre-
treated with standard atorvastatin (12) and in the aorta
of a normal rat. Average uptake in the atherosclerotic
aorta is approximately two times higher than the uptake
in the normal aorta (where baseline levels of the HMG-
CoA reductase are still present due to its ubiquitous
cytoplasmatic expression [72]), being the difference be-
tween these groups statistically significant (p = 0.004). In
the normal aorta, the uptake between control and ator-
vastatin (12) treated groups showed an average 49% ±
13% decrease in the binding efficiency of the radiotracer
(p = 0.0002). When comparing the uptake results be-
tween non-treated and treated atherosclerotic aorta, an
Fig. 6 In vitro autoradiography with [18F]atorvastatin ([18F]12) on the aorta counterparts of a normal and atherosclerotic rat model without
(control) and with (blocked) standard atorvastatin (12) pre-treatment
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average decrease of 56% ± 16% was seen in the binding
efficiency of the radiotracer (p = 0.0006).
Discussion
In this work, we explored the late-stage 18F-deoxyfluori-
nation of phenols via ruthenium π-complexes, to im-
prove our previous attempt to synthesize the β+ emitter
version of atorvastatin following the boronic acid pinacol
ester cross-coupling late-stage [18F]fluorination strategy
[73]. This widely clinically prescribed statin has evident
benefits in cardiovascular disease prevention and may
play a role in other conditions that still require further
elucidation. The adjustments used in this work for the
Ru-mediated 18F-deoxyfluorination strategy proved to be
an improvement compared to the previously reported
procedures [58–60], including halving the initial labeling
precursor amount, avoiding the use of different solvent
mixtures and salt additives, and omitting [18F]fluoride
washing and solvent removal procedures. This, together
with the simplicity of the process, the tolerance to a var-
iety of solvents (including aqueous solutions), and the
low reaction volumes used, might result in the Ru-
mediated deoxyfluorination strategy being suitable for
implementation in emerging techniques such as
microfluidics-lab-on-a-chip radiochemistry or microdro-
plet radiosynthesizers. By automating the optimized pro-
cedures, this radiofluorination strategy reliably produced
[18F]atorvastatin ([18F]12) in isolated radiochemical
yields of 19% ± 6% (d.c.). Within a synthesis time of ap-
proximately 80 min, the final injectable physiological so-
lution of the radiotracer was obtained with suitable
in vitro stability (at least upon 4 h), radiochemical purity
(> 95%), and molar activity (65 ± 32 GBq·μmol−1) to
evaluate its potential to be used as a PET imaging agent
for atherosclerosis.
The access to a radiolabeled analog of atorvastatin al-
lows the mapping and quantification of the radiotracer
uptake either in cellular and subcellular compartments
or in living complex organisms through high sensitive
nuclear analytical and imaging techniques. [18F]Atorva-
statin-PET might become a relevant research tool for
the assessment of statin-related mechanisms of action
and to discriminate between responsive and non-
responsive patients. Standard atorvastatin (12) is known
to occupy the binding site of HMG-CoA reductase with
high affinity (Ki approx. 14 nM [27]) and effectiveness
(IC50 approx. 8 nM [74]). Thus, the pre-treatment of the
liver sections with atorvastatin (12) hinders the access of
additional substrate to the active site. By incubating rat
liver sections, widely known to highly express HMG-
CoA reductase [65–67], with [18F]atorvastatin ([18F]12),
the expected selective binding to this enzyme was con-
firmed since a statistically significant decrease of the
uptake was observed when the hepatic tissue was pre-
treated with non-radioactive atorvastatin (12).
HMG-CoA reductase is known to be overexpressed in
atherosclerotic plaques, and its levels are correlated to
plaque instability and contribute to the risk of partial
rupture and detachment [75]. To evaluate the potential
of [18F]atorvastatin ([18F]12) as a PET tracer for athero-
sclerosis, an autoradiography imaging study was per-
formed on an excised aorta from an apolipoprotein E-
deficient rat model designed to develop atherosclerotic
plaques [71]. The uptake of the radiotracer was statisti-
cally significant higher in atherosclerotic aorta when
compared to a healthy rat aorta. Furthermore, the pre-
treatment with the reference compound 12 blocked
[18F]atorvastatin ([18F]12) binding, which supported the
potential of this PET tracer to be used for the specific
detection of atherosclerotic plaques. As a result of sev-
eral decades in clinical use, the toxicological profile of
atorvastatin (12) is widely known. Thus, first in human
studies that are already being envisaged at our Nuclear
Medicine Department are not being hampered by tox-
icity issues.
Conclusions
We have optimized the late-stage Ru-mediated 18F-deox-
yfluorination strategy performing the synthesis in an au-
tomated module (n = 10) with suitable radiochemical
purity (> 95%) and molar activity (65 ± 32 GBq·μmol−1).
The affinity of [18F]atorvastatin ([18F]12) to HMG-CoA
reductase and its potential to be used as a PET tracer for
atherosclerosis was confirmed in rat liver samples and
by comparison of the radiotracer uptake in the aorta of a
normal and atherosclerotic rat model. This radiotracer
can be a useful tool for the in vitro assessment of statin-
related mechanisms of action. Future clinical trials may
also be facilitated, as its toxicological profile is already




The syntheses of atorvastatin (12), labeling precursor 8,
and all intermediate compounds are described and char-
acterized in the Supporting Information file.
General procedure for the radiosynthesis of atorvastatin
([18F]12) by Ru-mediated deoxyfluorination
Cyclotron-produced aqueous [18F]fluoride was loaded
onto a polystyrene-divinylbenzene copolymers-based
HCO3
− anion exchange cartridge (Chromafix 45-PS-
HCO3−) preconditioned by sequentially pushing 3 mL of
K2C2O4 (10 mg/mL) and 2mL of water and dried with a
flow of Ar. Ru-coordinated labeling precursor 8
(2.5 μmol) and N,N-bis(2,6-diisopropylphenyl-1-
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chloroimidazolium chloride (13, 6.0 equiv.), with or
without a salt additive (see Table 1), were dissolved in
400 μL of a solvent (see Table 2). This solution was used
to elute the [18F]fluoride directly to a 3-mL glass Whea-
ton reaction V-vial or a 5-mL glass reactor from a Syn-
thra RNplus radiosynthesizer (containing a stirring bar).
The reaction mixture was left under vigorous stirring at
140 °C for 30 min. The intermediate species [18F]11 was
analyzed by radio-TLC (TLC-SG developed with hexane:
ethyl acetate (1:1 v:v), Rf ([18F]F-) = 0.0–0.1 and Rf
([18F]11) = 0.8–0–9) and radio-HPLC (SymmetryPrepTM
C18 7 μm 7.8 × 300 mm; A, sodium acetate 0.05M pH
4.7; B, acetonitrile; 0–4min, 90% A; 4–15min, 90% A to
20% A; 15–25 min, 20% A to 5% A; 25–33min, 5% A;
33–34min, 5% A to 90% A; 34–35 min, 90% A; flow, 6
mL/min; Rt ([18F]11) ≈ 24 min). To produce the final
product [18F]12, 1 mL of a methanol:HCl 6M (49:1 v:v)
solution was added to the reaction mixture and left to
stir at 60 °C for 5 min. Subsequently, 0.5 mL of a metha-
nol:aqueous NaOH 50% (9:1 v:v) solution was added to
the reaction mixture and left to stir at 60 °C for 5 min.
Production of [18F]12 was assessed by radio-TLC (TLC-
SG developed with ethanol:sodium phosphate 0.1M pH
7.4 (65:35 v:v), Rf ([18F]F-) = 0.0–0.1, Rf ([18F]11) = 0.5–
0.6, and Rf ([18F]12) = 0.8–0.9) and radio-HPLC (Rt
([18F]12) ≈ 16 min). Final reformulated product was ob-
tained after collecting the [18F]12 fraction by radio-
HPLC (SymmetryPrepTM C18 7 μm 7.8 × 300 mm; A,
sodium acetate 0.05M pH 4.7; B, acetonitrile; 0–4 min,
90% A; 4–15 min, 90% A to 20% A; 15–25 min, 20% A
to 5% A; 25–33min, 5% A; 33–34 min, 5% A to 90% A;
34–35min, 90% A; flow, 6 mL/min; Rt ([18F]12) ≈ 16
min; Rt ([18F]11) ≈ 24 min) and diluting it in 45 mL of
water. This bulk solution was then passed through an
Oasis HLB 1 cc cartridge (30 mg sorbent, Waters) to effi-
ciently trap [18F]12. The final radiotracer was then
washed with 10 mL of water and recovered with 0.5 mL
of ethanol. Final dilution in 5 mL of calcium acetate
0.05M pH 7.0 resulted in an isotonic and injectable
[18F]atorvastatin ([18F]12) solution. For the quality con-
trol (QC) of the final radiotracer and assessment of the
molar activity, a radio-UPLC system was used
(ACQUITY HSS T3 1.8 μm 3.0 × 50 mm column; A, so-
dium acetate 0.01M in H2O:MeOH:ACN 9:0.6:0.4 v:v:v;
B, sodium acetate 0.01M in H2O:MeOH:ACN 1:5.4:3.6
v:v:v; 0–2min, 100% A; 2–5min, 100% A to 40% A; 5–6
min, 40% to 0% A; 6–9 min, 0% A; 9–10 min, 0 to 100%
A; flow, 0.8 mL/min; UV 244 nm; Rt ([18F]12) ≈ 6.2 min).
Partition coefficient and stability evaluation
The log D was measured to determine the lipophilicity
of [18F]atorvastatin ([18F]12). The final reformulated ra-
diotracer (100 μL, in about 10% ethanol) was dissolved
in a mixture of 410 μL PBS (pH 7.4) and 490 μL n-
octanol in a microcentrifuge tube. This mixture was
strongly vortexed at room temperature and then centri-
fuged at 3000 rpm for 5min. Triplicate samples from
both organic and aqueous phases were collected and
measured on a ɣ-counter. The log D value was reported
as the average ratio between the number of counts in
the n-octanol (upper layer) and PBS (lower layer) ob-
tained in 4 independent measurements.
For the in vitro stability tests, final reformulated
[18F]12 was left at room temperature and analyzed by
radio-HPLC and radio-TLC at distinct time points up to
4 h. The in vitro stability assays were performed by incu-
bating 30 μL of [18F]12 (approx. 1.5 MBq) in 0.3 mL of
both human and Wistar rat serum, at 37 °C, up to 4 h
and analyzed by radio-TLC and radio-HPLC (in the lat-
ter case after protein precipitation with acetonitrile) at
various time points. All experiments were done in
triplicate.
Liver homogenate assay
Livers from Wistar rats were harvested, immediately fro-
zen in liquid nitrogen, and conserved at − 80 °C. For the
binding assay, tris-HCl (0.05M, pH 7.4) was added to
the thawed rat livers to obtain a final concentration of
20 mg/mL. The mixture was homogenized, using a Hei-
dolph DIAX 600 homogenizer, while being cooled in an
ice bath. Liver homogenate batches were stored at −
80 °C. For the binding assay, 300 μL of rat liver hom-
ogenate or Tris-HCl solution (for evaluation of the non-
specific binding (NSB) fraction of the radiotracer to the
tube walls) was added to each centrifuge tube. Tris-HCl
solution containing 0.3% human serum albumin was
added to reach a final volume of 475 μL and left for pre-
incubation for 15 min at room temperature. Then, 25 μL
of [18F]atorvastatin ([18F]12, approx. 1MBq) was added
to each assay tube, briefly vortexed, and then incubated
for 60 min under gentle shaking at room temperature.
Incubation was terminated by centrifuging (Rotanta
46RS Hettich zentrifugen) the assay tubes at 4 °C for 15
min (7500 rpm). The supernatant (S9 fraction containing
cytosol and microsomes) of each tube was transferred to
new tubes leaving the pellet (cell debris) in the original
tube. The content of NSB assay tubes was also pipetted
out to new tubes. All assay tubes were measured on a
Wallac Wizard 1480 ɣ-counter to calculate the percent-
age of radioactivity in each phase (S9 or pellet) with
NSB percentage being subtracted to the pellet results.
Autoradiographic imaging of rat liver
Harvested livers from four Wistar rats (n = 4) were sec-
tioned in three thin (1–2 mm) sagittal slices (1–2 mm).
To reduce the intervariability, each liver slice was di-
vided into two counterparts and distributed equally be-
tween the control and blocking groups (n = 4). The
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sections of each group were impregnated in 3.3 mL of
phosphate-buffered saline (PBS) enriched with glucose
(5.6 mM), MgCl2 (0.49 mM), and CaCl2 (0.68 mM) previ-
ously warmed at 37 °C. To the control group, 100 μL of
DMSO:polyethylene glycol sorbitan monolaurate (9:1 v:
v) was added. To the blocking group, 100 μL of atorva-
statin (2 mg in DMSO:polyethylene glycol sorbitan
monolaurate 9:1 v:v) was added to reach a total concen-
tration of 1 mM with a final volume of 3.5 mL. All liver
sections were left to incubate for 30 min. After the incu-
bation time, 100 μL of [18F]atorvastatin ([18F]12, approx.
4MBq) was added to each group and left to incubate for
1 h. Finally, the total volume of liquid in all groups was
carefully pipetted out and the liver slices were washed 3
times with 3 mL of cold PBS followed by 3 mL of iced
water. The slices were then carefully dried and imaged
with a GE Healthcare Amersham Typhoon autoradiog-
raphy system. The acquired data were analyzed with the
OptiQuant 03.00 software to quantify the radiotracer up-
take in digital luminescence units (DLU).
Autoradiographic imaging of rat normal and
atherosclerotic aorta
Harvested aortas from a healthy Wistar rat and from an
apolipoprotein E-deficient Wistar rat model for athero-
sclerosis [71] were transversely sectioned in 7 segments
each from the aortic arch to the suprarenal abdominal
aorta end. To reduce sample intervariability, since it is
not likely that the distribution of atherosclerotic plaque
is homogeneous throughout the total aortic length, each
segment was then opened and divided with a sagittal cut
in two counterparts. Each counterpart of the same seg-
ment was then distributed between two study groups:
non-blocked (control) and blocked with atorvastatin.
The exposed lumen was finally washed with PBS to
guarantee that any potential trace of blood was cleaned
out. Then, each aorta section was impregnated in 180 μL
of PBS enriched with glucose (5.6 mM), MgCl2 (0.49
mM), and CaCl2 (0.68 mM) previously warmed at 37 °C.
To the control group, 10 μL of DMSO:polyethylene gly-
col sorbitan monolaurate (9:1 v:v) was added. To the
blocking group, 10 μL of atorvastatin (0.1 mg in DMSO:
polyethylene glycol sorbitan monolaurate 9:1 v:v) was
added to reach a total concentration of 1 mM when in
the final 200 μL. All aorta sections were left to incubate
for 30 min. After the incubation time, 10 μL of [18F]ator-
vastatin ([18F]12, approx. 0.4 MBq) was added to each
group and left to incubate for 1 h. Finally, the total vol-
ume of liquid was carefully pipetted out and each aorta
section was washed 3 times with 250 μL of cold PBS
followed by 250 μL of iced water. The slices were then
carefully dried and imaged with a GE Healthcare Amer-
sham Typhoon autoradiography system. The acquired
data were analyzed with the OptiQuant 03.00 software
to quantify the radiotracer uptake in digital lumines-
cence units (DLU).
Statistics
Data are expressed as the mean ± standard deviation
(SD). Unpaired two-tailed t tests were used for statistical
evaluations. A p < 0.01 was considered statistically sig-
nificant. Statistical analyses of data were performed
using GraphPad Prism version 6.01 for Windows
(GraphPad Software, La Jolla, CA, USA).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13550-020-00622-4.
Additional file 1:. Supporting Information file.
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